Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs

Junki Maruyama, Elizabeth J. Mateer, John T. Manning, Rachel Sattler, Alexey V. Seregin, Natalya Bukreyeva, Frank R. Jones, Joseph P. Balint, Elizabeth S. Gabitzsch, Cheng Huang, Slobodan Paessler

Research output: Contribution to journalArticle

Abstract

Lassa virus (LASV), the causative agent of Lassa fever (LF), was first identified in 1969. Since then, outbreaks in the endemic countries of Nigeria, Liberia, and Sierra Leone occur on an annual basis resulting in a case-fatality rate of 15–70% in hospitalized patients. There is currently no licensed vaccine and there are limited animal models to test vaccine efficacy. An estimated 37.7 million people are at risk of contracting LASV; therefore, there is an urgent need for the development of a safe, effective vaccine against LASV infection. The LF endemic countries are also inflicted with HIV, Ebola, and malaria infections. The safety in immunocompromised populations must be considered in LASV vaccine development. The novel adenovirus vector-based platform, Ad5 (E1-,E2b-) has been used in clinical trial protocols for treatment of immunocompromised individuals, has been shown to exhibit high stability, low safety risk in humans, and induces a strong cell-mediated and pro-inflammatory immune response even in the presence of pre-existing adenovirus immunity. To this nature, our lab has developed an Ad5 (E1-,E2b-) vector-based vaccine expressing the LASV-NP or LASV-GPC. We found that guinea pigs vaccinated with two doses of Ad5 (E1-,E2b-) LASV-NP and Ad5 (E1-,E2b-) LASV-GPC were protected against lethal LASV challenge. The Ad5 (E1-,E2b-) LASV-NP and LASV-GPC vaccine represents a potential vaccine candidate against LF.

Original languageEnglish (US)
Pages (from-to)6824-6831
Number of pages8
JournalVaccine
Volume37
Issue number45
DOIs
StatePublished - Oct 23 2019

Fingerprint

Lassa virus
Lassa Fever
guinea pigs
fever
Guinea Pigs
Vaccines
vaccines
immunocompromised population
Adenoviridae
Clinical Protocols
Ebola Hemorrhagic Fever
Liberia
Sierra Leone
Safety
vaccine development
Virus Diseases
Nigeria

Keywords

  • Adenovirus vector
  • Lassa fever
  • Lassa virus
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs. / Maruyama, Junki; Mateer, Elizabeth J.; Manning, John T.; Sattler, Rachel; Seregin, Alexey V.; Bukreyeva, Natalya; Jones, Frank R.; Balint, Joseph P.; Gabitzsch, Elizabeth S.; Huang, Cheng; Paessler, Slobodan.

In: Vaccine, Vol. 37, No. 45, 23.10.2019, p. 6824-6831.

Research output: Contribution to journalArticle

Maruyama, Junki ; Mateer, Elizabeth J. ; Manning, John T. ; Sattler, Rachel ; Seregin, Alexey V. ; Bukreyeva, Natalya ; Jones, Frank R. ; Balint, Joseph P. ; Gabitzsch, Elizabeth S. ; Huang, Cheng ; Paessler, Slobodan. / Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs. In: Vaccine. 2019 ; Vol. 37, No. 45. pp. 6824-6831.
@article{9d96a85bef9540869a3b90a68409aa1f,
title = "Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs",
abstract = "Lassa virus (LASV), the causative agent of Lassa fever (LF), was first identified in 1969. Since then, outbreaks in the endemic countries of Nigeria, Liberia, and Sierra Leone occur on an annual basis resulting in a case-fatality rate of 15–70{\%} in hospitalized patients. There is currently no licensed vaccine and there are limited animal models to test vaccine efficacy. An estimated 37.7 million people are at risk of contracting LASV; therefore, there is an urgent need for the development of a safe, effective vaccine against LASV infection. The LF endemic countries are also inflicted with HIV, Ebola, and malaria infections. The safety in immunocompromised populations must be considered in LASV vaccine development. The novel adenovirus vector-based platform, Ad5 (E1-,E2b-) has been used in clinical trial protocols for treatment of immunocompromised individuals, has been shown to exhibit high stability, low safety risk in humans, and induces a strong cell-mediated and pro-inflammatory immune response even in the presence of pre-existing adenovirus immunity. To this nature, our lab has developed an Ad5 (E1-,E2b-) vector-based vaccine expressing the LASV-NP or LASV-GPC. We found that guinea pigs vaccinated with two doses of Ad5 (E1-,E2b-) LASV-NP and Ad5 (E1-,E2b-) LASV-GPC were protected against lethal LASV challenge. The Ad5 (E1-,E2b-) LASV-NP and LASV-GPC vaccine represents a potential vaccine candidate against LF.",
keywords = "Adenovirus vector, Lassa fever, Lassa virus, Vaccine",
author = "Junki Maruyama and Mateer, {Elizabeth J.} and Manning, {John T.} and Rachel Sattler and Seregin, {Alexey V.} and Natalya Bukreyeva and Jones, {Frank R.} and Balint, {Joseph P.} and Gabitzsch, {Elizabeth S.} and Cheng Huang and Slobodan Paessler",
year = "2019",
month = "10",
day = "23",
doi = "10.1016/j.vaccine.2019.09.030",
language = "English (US)",
volume = "37",
pages = "6824--6831",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "45",

}

TY - JOUR

T1 - Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs

AU - Maruyama, Junki

AU - Mateer, Elizabeth J.

AU - Manning, John T.

AU - Sattler, Rachel

AU - Seregin, Alexey V.

AU - Bukreyeva, Natalya

AU - Jones, Frank R.

AU - Balint, Joseph P.

AU - Gabitzsch, Elizabeth S.

AU - Huang, Cheng

AU - Paessler, Slobodan

PY - 2019/10/23

Y1 - 2019/10/23

N2 - Lassa virus (LASV), the causative agent of Lassa fever (LF), was first identified in 1969. Since then, outbreaks in the endemic countries of Nigeria, Liberia, and Sierra Leone occur on an annual basis resulting in a case-fatality rate of 15–70% in hospitalized patients. There is currently no licensed vaccine and there are limited animal models to test vaccine efficacy. An estimated 37.7 million people are at risk of contracting LASV; therefore, there is an urgent need for the development of a safe, effective vaccine against LASV infection. The LF endemic countries are also inflicted with HIV, Ebola, and malaria infections. The safety in immunocompromised populations must be considered in LASV vaccine development. The novel adenovirus vector-based platform, Ad5 (E1-,E2b-) has been used in clinical trial protocols for treatment of immunocompromised individuals, has been shown to exhibit high stability, low safety risk in humans, and induces a strong cell-mediated and pro-inflammatory immune response even in the presence of pre-existing adenovirus immunity. To this nature, our lab has developed an Ad5 (E1-,E2b-) vector-based vaccine expressing the LASV-NP or LASV-GPC. We found that guinea pigs vaccinated with two doses of Ad5 (E1-,E2b-) LASV-NP and Ad5 (E1-,E2b-) LASV-GPC were protected against lethal LASV challenge. The Ad5 (E1-,E2b-) LASV-NP and LASV-GPC vaccine represents a potential vaccine candidate against LF.

AB - Lassa virus (LASV), the causative agent of Lassa fever (LF), was first identified in 1969. Since then, outbreaks in the endemic countries of Nigeria, Liberia, and Sierra Leone occur on an annual basis resulting in a case-fatality rate of 15–70% in hospitalized patients. There is currently no licensed vaccine and there are limited animal models to test vaccine efficacy. An estimated 37.7 million people are at risk of contracting LASV; therefore, there is an urgent need for the development of a safe, effective vaccine against LASV infection. The LF endemic countries are also inflicted with HIV, Ebola, and malaria infections. The safety in immunocompromised populations must be considered in LASV vaccine development. The novel adenovirus vector-based platform, Ad5 (E1-,E2b-) has been used in clinical trial protocols for treatment of immunocompromised individuals, has been shown to exhibit high stability, low safety risk in humans, and induces a strong cell-mediated and pro-inflammatory immune response even in the presence of pre-existing adenovirus immunity. To this nature, our lab has developed an Ad5 (E1-,E2b-) vector-based vaccine expressing the LASV-NP or LASV-GPC. We found that guinea pigs vaccinated with two doses of Ad5 (E1-,E2b-) LASV-NP and Ad5 (E1-,E2b-) LASV-GPC were protected against lethal LASV challenge. The Ad5 (E1-,E2b-) LASV-NP and LASV-GPC vaccine represents a potential vaccine candidate against LF.

KW - Adenovirus vector

KW - Lassa fever

KW - Lassa virus

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85072567542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072567542&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.09.030

DO - 10.1016/j.vaccine.2019.09.030

M3 - Article

C2 - 31561999

AN - SCOPUS:85072567542

VL - 37

SP - 6824

EP - 6831

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 45

ER -